The company had posted a standalone net profit of Rs 220.58 crore in the same period last fiscal, it said in a BSE filing.
Net sales during the period under review rose by 8 per cent to Rs 851.77 crore as against Rs 788.08 crore in the year-ago period.
The company, which is primarily engaged in manufacturing of active pharmaceutical ingredients and intermediates, said during the quarter it had a forex gain of Rs 3 crore as against Rs 11 crore in the corresponding period last fiscal.